Peptide-MHC complexes (pMHC) can be bound by cognate T cell receptors (TCRs) complexed with CD8 or CD4 (for HLA-I and HLA-II respectively) to trigger anti-tumor immune function. The gene discussed is HLA-C; the disease is neoplasm.